The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Cancer Immunology, Immunotherapy

Volumn 66, Issue 11, 2017, Pages 1425-1436

  Thistlethwaite, Fiona C ^a,b   Gilham, David E ^b,g   Guest, Ryan D ^b,g   Rothwell, Dominic G ^c   Pillai, Manon ^a,b   Burt, Deborah J ^c   Byatte, Andrea J ^a   Kirillova, Natalia ^b,g   Valle, Juan W ^a,b   Sharma, Surinder K ^d   Chester, Kerry A ^d   Westwood, Nigel B ^e   Halford, Sarah E R ^e   Nabarro, Stephen ^e   Wan, Susan ^e   Austin, Eric ^f   Hawkins, Robert E ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f NHS BLOOD AND TRANSPLANT   (United Kingdom)

^g Cellular Therapeutics Ltd   (United Kingdom)

Author keywords

CEA; Chimeric antigen receptor; Persistence; T cells; Toxicity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; CEACAM5 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MYELOABLATIVE AGENT; VIDARABINE;

ADULT; ADVANCED CANCER; AGED; AIR CONDITIONING; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CELL MIGRATION; CELL SURVIVAL; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CYTOKINE RELEASE; DECREASED APPETITE; ENGRAFTMENT; FEMALE; HUMAN; IN VIVO STUDY; INFUSION; LIFE EXPECTANCY; LUNG EPITHELIUM; LUNG INFILTRATE; LUNG TOXICITY; MALE; OPEN STUDY; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; SEPSIS; T LYMPHOCYTE; TACHYPNEA; ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; AGONISTS; ANALOGS AND DERIVATIVES; ANEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG; METABOLISM; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; PROCEDURES; TRANSPLANTATION; TREATMENT OUTCOME; VOMITING;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-6; LUNG; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME; VIDARABINE; VOMITING;

EID: 85025163642     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2034-7     Document Type: Article

References (41)

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38
2. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25
3. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549
4. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528
5. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507–1517
6. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139
7. Ramos CA, Heslop HE, Brenner MK (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165–183
8. Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62–68
9. Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA (2015) Adoptive cell therapy–tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin Oncol 42:626–639
10. Curran KJ, Brentjens RJ (2015) Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol 33:1703–1706
11. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106–6115
12. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20–e22
13. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J et al (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72–82
14. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264–1270
15. Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197–2207
16. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP et al (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979–984
17. Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A et al (2000) Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Mark 16:53–62
18. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et al (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12:6509–6516
19. Gilham DE, O’Neil A, Hughes C, Guest RD, Kirillova N, Lehane M et al (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 25:139–151
20. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O’Neill A et al (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28:203–211
21. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H (2007) T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 178:4650–4657
22. Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE et al (2003) Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 46:793–804
23. Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE (2003) T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 88:1119–1127
24. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ et al (2001) Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 166:182–187
25. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233–5239
26. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419
27. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028
28. Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ et al (2014) Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother 63:133–145
29. Shi ZR, Tacha D, Itzkowitz SH (1994) Monoclonal antibody COL-1 reacts with restricted epitopes on carcinoembryonic antigen: an immunohistochemical study. J Histochem Cytochem 42:1215–1219
30. Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME (2012) Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med 10:69
31. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE (2010) Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10:77–90
32. Klebanoff CA, Rosenberg SA, Restifo NP (2016) Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22:26–36
33. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA + liver metastases. Clin Cancer Res 21:3149–3159
34. Pegram HJ, Park JH, Brentjens RJ (2014) CD28z CARs and armored CARs. Cancer J 20:127–133
35. Ahnen DJ, Nakane PK, Brown WR (1982) Ultrastructural localization of carcinoembryonic antigen in normal intestine and colon cancer: abnormal distribution of CEA on the surfaces of colon cancer cells. Cancer 49:2077–2090
36. Boehm MK, Corper AL, Wan T, Sohi MK, Sutton BJ, Thornton JD et al (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 346(Pt 2):519–528
37. Kim J, Kaye FJ, Henslee JG, Shively JE, Park JG, Lai SL et al (1992) Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer 52:718–725
38. Klaile E, Klassert TE, Scheffrahn I, Muller MM, Heinrich A, Heyl KA et al (2013) Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respir Res 14:85
39. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851
40. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620–626
41. Johnson L, June C (2017) Driving gene-engineered T cell immunnotherapy of cancer. Cell Res 27:38–58